Preclinical data presented at the 95th annual meeting of the American Association of Cancer Research (AACR) demonstrate that INGN 241 enhances the anti-tumor effects of Herceptin® (Trastuzumab) in HER2-positive breast cancer.

INGN 241 a novel product candidate designed to deliver the MDA-7/IL-24 gene to tumor cells is being developed by Introgen Therapeutics Inc. (Nasdaq: INGN - News) and is in Phase 1 and Phase 2 clinical trials in a variety of cancers. The data were generated in an ongoing collaboration between researchers at Introgen and The University of Texas M. D. Anderson Cancer Center.